Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan
Open Access
- 1 December 2021
- journal article
- research article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 17, 3781-3790
Abstract
Aim: Antidepressants, including selective serotonin reuptake inhibitors, often elicit a poor response in patients with major depressive disorder (MDD) with significant anxiety symptoms. This study investigated the effects of the multimodal antidepressant vortioxetine in patients with MDD and associated anxiety. Methods: This was a post hoc analysis of data from an 8-week, randomized, double-blind, placebo-controlled, Phase 3 study of vortioxetine (10 mg or 20 mg) in Japanese patients aged 20– 75 years with recurrent MDD and a Montgomery–Åsberg Depression Rating Scale (MADRS) score of at least 26. Changes from baseline to week 8 in MADRS total score and Hamilton Depression Rating Scale (HAM-D) anxiety/somatization factor score were assessed in patients with anxious depression (HAM-D anxiety/somatization factor score ≥ 7) and without anxious depression. Results: Data were available for 489 patients. In patients with anxious depression, the least-squares (LS) mean difference (95% confidence interval [CI]) versus placebo in change in MADRS total score was − 3.44 (− 6.10, − 0.77) for vortioxetine 10 mg and − 4.51 (− 7.15, − 1.87) for vortioxetine 20 mg. In patients with non-anxious depression, the LS mean difference (95% CI) versus placebo was − 1.81 (− 4.71, 1.09) and − 1.05 (− 4.00, 1.90) for vortioxetine 10 mg and 20 mg, respectively. Changes from baseline in HAM-D anxiety/somatization factor score were greater in patients treated with vortioxetine 10 mg or 20 mg than in those treated with placebo. Conclusion: Vortioxetine may be effective for patients with anxiety symptoms in MDD. Further research is warranted to investigate these effects in a real-world clinical setting. Clinical Trials Registration: ClinicalTrials.gov identifier for primary study: NCT02389816.Keywords
This publication has 36 references indexed in Scilit:
- Severe and anxious depression: Combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitorsEuropean Neuropsychopharmacology, 2012
- Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary careInternational Journal of Psychiatry in Clinical Practice, 2012
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInternational Journal of Neuropsychopharmacology, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Prevalence and Treatment Outcome in Anxious Versus Nonanxious DepressionThe Journal of Clinical Psychiatry, 2010
- Current perspectives of the roles of the central norepinephrine system in anxiety and depressionDepression and Anxiety, 2010
- Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trialsDepression and Anxiety, 2009
- Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the Treatment of Major Depressive Disorder With High Levels of Anxiety (Anxious Depression)The Journal of Clinical Psychiatry, 2008
- Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D ReportAmerican Journal of Psychiatry, 2008
- Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*DPsychological Medicine, 2004